ストックスクリーナーアプリを入手
11.19
4.59%
0.5212
Corbus Pharmaceuticals Holdings Inc (CRBP) 最新ニュース
Colliers Facilitates Lease Renewal for Corbus Pharmaceuticals in Norwood - Boston Real Estate Times
Avoiding Lag: Real-Time Signals in (CRBP) Movement - Stock Traders Daily
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings to unveil new CRB-701 clinical results at ASCO annual meeting - Traders Union
Corbus to unpack 75-patient head and neck cancer data at June 1 ASCO panel - Stock Titan
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026 - The Manila Times
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
MSN Money - MSN
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Rating Upgraded by Guggenheim - MarketBeat
Guggenheim initiates coverage of Corbus Pharmaceuticals Holdings (CRBP) with buy recommendation - MSN
Corbus reaches FDA agreement on development path for cancer drug CRB-701 - MSN
CRBP Initiates Coverage On Guggenheim -- Rating Set to Buy - GuruFocus
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals (CRBP) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Corbus offers upside despite post-FDA update, analyst highlights competitive edge - MSN
Corbus Pharmaceuticals slumps 17%, prices $75M at $13 per share - MSN
Corbus Pharmaceuticals (NASDAQ:CRBP) Share Price Crosses Above Fifty Day Moving AverageShould You Sell? - MarketBeat
Discipline and Rules-Based Execution in CRBP Response - Stock Traders Daily
Corbus Pharmaceuticals (NASDAQ:CRBP) Upgraded by Wall Street Zen to "Sell" Rating - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus Pharmaceuticals (CRBP) Q4 2025 earnings summary - Quartr
Corbus Pharmaceuticals (CRBP) Corporate presentation Summary - Quartr
Corbus Pharmaceuticals (CRBP) Registration Filing Summary - Quartr
Corbus Pharmaceuticals (CRBP) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary - Quartr
Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701 - The Manila Times
Corbus brings new cervical and head-neck cancer data to ASCO - Stock Titan
CRBP Stock Price, Quote & Chart | CORBUS PHARMACEUTICALS HOLDI (NASDAQ:CRBP) - ChartMill
Corbus Pharmaceuticals Aligns with FDA on Cancer Drug Strategy - HarianBasis.co
Mizuho Sees Strong Risk-Reward in Corbus Pharmaceuticals Holdings, Inc. (CRBP) Near Cash Value - Insider Monkey
Corbus Pharmaceuticals updates executive employment agreements for CEO and CFO - Investing.com UK
Corbus Pharmaceuticals updates executive employment agreements for CEO and CFO By Investing.com - Investing.com South Africa
Corbus Pharmaceuticals Updates Executive Employment Agreements and Protections - TipRanks
Corbus Pharmaceuticals (NASDAQ: CRBP) resets CEO and CFO pay, severance and CIC terms - Stock Titan
Corbus Pharmaceuticals synthesizes new cannabinoid CB1 receptor antagonists or inverse agonists - BioWorld News
5 Best Biotech Stocks Under $10 to Buy - Insider Monkey
Corbus Advances CANYON-1 Phase 1b Obesity Trial Milestone - The Globe and Mail
Corbus Pharmaceuticals (CRBP) Advances in Obesity Treatment Tria - GuruFocus
Corbus completes enrollment in obesity drug trial By Investing.com - Investing.com Australia
Corbus completes enrollment in obesity drug trial - Investing.com
Corbus Pharmaceuticals Holdings initiates last patient first visit in CANYON-1 obesity trial with 240 participants - Traders Union
0.78%
3.01%
大文字化:
|
ボリューム (24 時間):